NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Acrivon Therapeutics logo
$1.15 -0.25 (-17.86%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.20 +0.06 (+4.78%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Acrivon Therapeutics Stock (NASDAQ:ACRV)

Advanced

Key Stats

Today's Range
$0.97
▼
$1.40
50-Day Range
$1.15
▼
$2.15
52-Week Range
$0.97
▼
$3.56
Volume
1.29 million shs
Average Volume
197,944 shs
Market Capitalization
$49.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50
Consensus Rating
Moderate Buy

Company Overview

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy.

The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Founded in 2018 and headquartered in Watertown, Massachusetts, Acrivon conducts drug development and clinical research. The company was co-founded by Peter Blume-Jensen, M.D., Ph.D., who serves as its chief executive officer.

AI Generated. May Contain Errors.

Acrivon Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ACRV MarketRank™: 
3.09009009009 of 5 stars

Acrivon Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 211th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Acrivon Therapeutics has a consensus price target of $13.50, representing about 1,073.9% upside from its current price of $1.15.

  • Amount of Analyst Coverage

    Acrivon Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Acrivon Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Acrivon Therapeutics are expected to grow in the coming year, from ($1.69) to ($1.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acrivon Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acrivon Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acrivon Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.71% of the float of Acrivon Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Acrivon Therapeutics has a short interest ratio ("days to cover") of 11.37, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Acrivon Therapeutics has recently increased by 3.85%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Acrivon Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Acrivon Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Acrivon Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Acrivon Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,320.00 in company stock.

  • Percentage Held by Insiders

    10.50% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acrivon Therapeutics' insider trading history.
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACRV Stock News Headlines

Wall Street Zen Upgrades Acrivon Therapeutics (NASDAQ:ACRV) to Hold
Acrivon Reports Phase 1/2 ACR-2316 Dose-Escalation Results
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Headlines

ACRV Stock Analysis - Frequently Asked Questions

Acrivon Therapeutics' stock was trading at $2.41 at the beginning of the year. Since then, ACRV stock has decreased by 52.3% and is now trading at $1.15.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its earnings results on Monday, November, 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

Top institutional investors of Acrivon Therapeutics include Marshall Wace LLP (1.27%), State Street Corp (0.16%), Empowered Funds LLC (0.13%) and StoneX Group Inc. (0.05%). Insiders that own company stock include Perceptive Advisors Llc, Peter Blume-Jensen, Eric Devroe, Mary Miller, Adam D Levy and Adam D Levy.
View institutional ownership trends
.

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Biomea Fusion (BMEA), Archer Aviation (ACHR), Lithium Americas (LAC) and Energy Transfer (ET).

Company Calendar

Last Earnings
11/16/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACRV
CIK
1781174
Fax
N/A
Employees
76
Year Founded
N/A

Price Target and Rating

High Price Target
$19.00
Low Price Target
$8.00
Potential Upside/Downside
+1,073.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.90 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-75.22%
Return on Assets
-65.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.99
Quick Ratio
7.99

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.57 per share
Price / Book
0.32

Miscellaneous

Outstanding Shares
42,850,000
Free Float
38,403,000
Market Cap
$49.28 million
Optionable
Not Optionable
Beta
1.96
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ACRV) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners